MyFinsight
Home
Blog
About
Contact
Download
Download image
Maturities of
available-for-sale securities
$173,950K
Proceeds from the
issuance of common stock...
$9,986K
Proceeds from sales of
common stock, pursuant...
$371K
Net cash provided by
(used in) investing...
$41,228K
Net cash provided by
financing activities
$10,305K
Canceled cashflow
$132,722K
Canceled cashflow
$52K
Net (decrease)
increase in cash and cash...
-$30,951K
Canceled cashflow
$51,533K
In-process research and
development impairment
$10,000K
Share-based compensation
$8,966K
Depreciation expense and
amortization
$3,251K
Accrued personnel
expenses
$2,011K
Prepaid expenses and
other current assets
-$624K
Other noncurrent
liabilities
$331K
Foreign currency
adjustments
-$250K
Accounts payable and
accrued expenses
$147K
Accounts receivable
-$110K
Other, net
-$5K
Purchases of
available-for-sale securities
$119,838K
Additions to property and
equipment
$12,749K
Additions to other assets
$135K
Repayment of notes payable
$52K
Net cash used in
operating activities
-$82,484K
Canceled cashflow
$25,695K
Net loss
-$103,121K
Net accretion of
discounts on...
-$2,723K
Deferred income
-$1,400K
Deferred income tax
benefit
-$793K
Interest receivable
$142K
Back
Back
Cash Flow
source: myfinsight.com
Perspective Therapeutics, Inc. (CATX)
Perspective Therapeutics, Inc. (CATX)